Differential induction of muscle atrophy pathways in two mouse models of spinal muscular atrophy

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Deguise, Marc Olivier ^a,b   Boyer, Justin G ^a,b,c   McFall, Emily R ^a   Yazdani, Armin ^a,b   De Repentigny, Yves ^a   Kothary, Rashmi ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BNIP3 PROTEIN, MOUSE; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, MOUSE; FOXO4 PROTEIN, MOUSE; HYDROXAMIC ACID; MEMBRANE PROTEIN; MITOCHONDRIAL PROTEIN; SURVIVAL MOTOR NEURON PROTEIN 2; TRANSCRIPTION FACTOR FKHRL1; TRICHOSTATIN A;

ANIMAL; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; MUSCLE ATROPHY; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SPINAL MUSCULAR ATROPHY; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ANIMALS; DISEASE MODELS, ANIMAL; FORKHEAD BOX PROTEIN O3; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; HUMANS; HYDROXAMIC ACIDS; MEMBRANE PROTEINS; MICE, KNOCKOUT; MICROSCOPY, ELECTRON, TRANSMISSION; MITOCHONDRIAL PROTEINS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; MUSCULAR ATROPHY, SPINAL; SIGNAL TRANSDUCTION; SURVIVAL OF MOTOR NEURON 2 PROTEIN;

EID: 84976527076     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep28846     Document Type: Article

References (58)

1. Pearn, J. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J. Med. Genet. 15, 409-13 (1978).
2. Prior, T. W. et al. Newborn and carrier screening for spinal muscular atrophy. Am. J. Med. Genet. A 152A, 1608-16 (2010).
3. Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155-65 (1995).
4. Lorson, C. L., Hahnen, E., Androphy, E. J. & Wirth, B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. USA 96, 6307-11 (1999).
5. Boyer, J., Bowerman, M. & Kothary, R. The many faces of SMN: deciphering the function critical to spinal muscular atrophy pathogenesis. Future Neurol. 5, 873-90 (2010).
6. Schrank, B. et al. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc. Natl. Acad. Sci. USA 94, 9920-5 (1997).
7. Monani, U. R. et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum. Mol. Genet. 9, 333-9 (2000).
8. Hammond, S. M. et al. Mouse survival motor neuron alleles that mimic SMN2 splicing and are inducible rescue embryonic lethality early in development but not late. PLos ONE 5, e15887 (2010).
9. Bowerman, M., Murray, L. M., Beauvais, A., Pinheiro, B. & Kothary, R. A critical smn threshold in mice dictates onset of an intermediate spinal muscular atrophy phenotype associated with a distinct neuromuscular junction pathology. Neuromuscul. Disord. 22, 263-76 (2012).
10. Boyer, J. G. et al. Early onset muscle weakness and disruption of muscle proteins in mouse models of spinal muscular atrophy. Skelet Muscle 3, 24 (2013).
11. Boyer, J. G. et al. Myogenic program dysregulation is contributory to disease pathogenesis in spinal muscular atrophy. Hum. Mol. Genet. 23, 4249-59 (2014).
12. Bricceno, K. V. et al. Survival motor neuron protein deficiency impairs myotube formation by altering myogenic gene expression and focal adhesion dynamics. Hum. Mol. Genet. 23, 4745-57 (2014).
13. Lecker, S. et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18, 39-51 (2004).
14. Sacheck, J. M. et al. Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J. 21, 140-55 (2007).
15. Moresi, V. et al. Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases. Cell 143, 35-45 (2010).
16. Macpherson, P. C., Wang, X. & Goldman, D. Myogenin regulates denervation-dependent muscle atrophy in mouse soleus muscle. J. Cell. Biochem. 112, 2149-59 (2011).
17. Bricceno, K. V. et al. Histone deacetylase inhibition suppresses myogenin-dependent atrogene activation in spinal muscular atrophy mice. Hum. Mol. Genet. 21, 4448-59 (2012).
18. Avila, A. M. et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J. Clin. Invest. 117, 659-71 (2007).
19. Liu, H., Yazdani, A., Murray, L. M., Beauvais, A. & Kothary, R. The Smn-independent beneficial effects of trichostatin A on an intermediate mouse model of spinal muscular atrophy. PLos ONE 9, e101225 (2014).
20. Iyer, C. C., McGovern, V. L., Wise, D. O., Glass, D. J. & Burghes, A. H. Deletion of atrophy enhancing genes fails to ameliorate the phenotype in a mouse model of spinal muscular atrophy. Neuromuscul. Disord. 24, 436-44 (2014).
21. Milan, G. et al. Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy. Nat. Commun. 6, 6670 (2015).
22. Sandri, M. et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117, 399-412 (2004).
23. Mammucari, C. et al. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. 6, 458-71 (2007).
24. Shababi, M. et al. Partial restoration of cardio-vascular defects in a rescued severe model of spinal muscular atrophy. J. Mol. Cell. Cardiol. 52, 1074-82 (2012).
25. Bodine et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294, 1704-8 (2001).
26. Schiaffino, S. & Mammucari, C. Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. Skeletal Muscle 1, 4 (2011).
27. Sandri, M. Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome. Int. J. Biochem. Cell Biol. 45, 2121-9 (2013).
28. Roy, S., Dubowitz, V. & Wolman, L. Ultrastructure of muscle in infantile spinal muscular atrophy. J. Neurol. Sci. 12, 219-32 (1971).
29. Szliwowski, H. B. & Drochmans, P. Ultrastructural aspects of muscle and nerve in Werdnig-Hoffmann disease. Acta Neuropathol. 31, 281-96 (1975).
30. Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8, 445-544 (2012).
31. Weidberg, H. et al. LC3 and GATE-16/GABARAP subfamilies are both essential yet act differently in autophagosome biogenesis. EMBO J. 29, 1792-802 (2010).
32. Bjorkoy, G. et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J. Cell Biol. 171, 603-14 (2005).
33. Millino, C. et al. Different atrophy-hypertrophy transcription pathways in muscles affected by severe and mild spinal muscular atrophy. BMC Med. 7, 14 (2009).
34. Bosma, M. et al. Perilipin 2 improves insulin sensitivity in skeletal muscle despite elevated intramuscular lipid levels. Diabetes 61, 2679-90 (2012).
35. Senf, S. M., Dodd, S. L. & Judge, A. R. FOXO signaling is required for disuse muscle atrophy and is directly regulated by Hsp70. Am. J. Physiol. Cell Physiol. 298, C38-45 (2010).
36. Senf, S. M., Sandesara, P. B., Reed, S. A. & Judge, A. R. p300 Acetyltransferase activity differentially regulates the localization and activity of the FOXO homologues in skeletal muscle. Am. J. Physiol. Cell Physiol. 300, C1490-501 (2011).
37. Bertaggia, E., Coletto, L. & Sandri, M. Posttranslational modifications control FoxO3 activity during denervation. Am J Physiol. Cell Physiol. 302, C587-96 (2012).
38. Essaghir, A., Dif, N., Marbehant, C. Y., Coffer, P. J. & Demoulin, J.-B. B. The transcription of FOXO genes is stimulated by FOXO3 and repressed by growth factors. J. Biol. Chem. 284, 10334-42 (2009).
39. Skurk, C. et al. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J. Biol. Chem. 280, 20814-23 (2005).
40. Sengupta, A., Molkentin, J. D. & Yutzey, K. E. FoxO transcription factors promote autophagy in cardiomyocytes. J. Biol. Chem. 284, 28319-31 (2009).
41. Schips, T. G. et al. FoxO3 induces reversible cardiac atrophy and autophagy in a transgenic mouse model. Cardiovasc. Res. 91, 587-97 (2011).
42. Zhao, J. et al. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. 6, 472-83 (2007).
43. Le, T. T. et al. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum. Mol. Genet. 14, 845-57 (2005).
44. Martinez-Hernandez, R. et al. The developmental pattern of myotubes in spinal muscular atrophy indicates prenatal delay of muscle maturation. J. Neuropathol. Exp. Neurol. 68, 474-81 (2009).
45. Rose, F. F., Mattis, V. B., Rindt, H. & Lorson, C. L. Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy. Hum. Mol. Genet. 18, 997-1005 (2009).
46. Sumner, C. J. et al. Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice. Hum. Mol. Genet. 18, 3145-52 (2009).
47. Bosch-Marce, M. et al. Increased IGF-1 in muscle modulates the phenotype of severe SMA mice. Hum. Mol. Genet. 20, 1844-53 (2011).
48. Ling, K. K., Gibbs, R. M., Feng, Z. & Ko, C.-P. P. Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy. Hum. Mol. Genet. 21, 185-95 (2012).
49. Heier, C. R., Satta, R., Lutz, C. & DiDonato, C. J. Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice. Hum. Mol. Genet. 19, 3906-18 (2010).
50. Ting, C.-H. H., Lin, C.-W. W., Wen, S.-L. L., Hsieh-Li, H.-M. M. & Li, H. Stat5 constitutive activation rescues defects in spinal muscular atrophy. Hum. Mol. Genet. 16, 499-514 (2007).
51. Beharry, Sandesara & Roberts. H. D. A. C.1 activates FoxO and is both sufficient and required for skeletal muscle atrophy. J. Cell Sci. 127, 1441-53 (2014).
52. Menke, L. A., Poll-The, B. T., Clur, S. A., Bilardo, C. M., van der Wal, A. C., Lemmink, H. H. & Cobben, J. M. Congenital heart defects in spinal muscular atrophy type I: a clinical report of two siblings and a review of the literature. Am. J. Med. Genet. 146A, 740-44 (2008).
53. Rudnik-Schoneborn, S. et al. Congenital heart disease is a feature of severe infantile spinal muscular atrophy. J. Med. Genet. 45, 635-8 (2008).
54. Moller et al. Spinal muscular atrophy type I combined with atrial septal defect in three sibs. Clin. Genet. 38, 81-83 (1990).
55. Shababi, M. et al. Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum. Mol. Genet. 19, 4059-71 (2010).
56. Bevan, A. K. et al. Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum. Mol. Genet. 19, 3895-905 (2010).
57. Foust, K. D. et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotechnol. 28, 271-4 (2010).
58. Shafey, D., Boyer, J. G., Bhanot, K. & Kothary, R. Identification of novel interacting protein partners of SMN using tandem affinity purification. J. Proteome Res. 9, 1659-69 (2010).